Skip to main content
Premium Trial:

Request an Annual Quote

Investor Recommends Celera Spin Out Merck Royalty Asset

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – An investment fund has filed a document with the US Securities and Exchange Commission recommending that Celera spin out, segregate, or distribute its royalty asset that is associated with a Merck drug candidate currently in Phase III studies.

Biotechnology Value Fund filed the Schedule 13D two days ago. The fund and its affiliates own nearly 10 percent of Celera's 81.9 million shares outstanding, as of its last 10-Q, which was filed with the SEC on Nov. 9, 2009.

BVF said in the filing this week that it believes "significant shareholder value could be unlocked" if Celera were to spin out or distribute the royalty asset. That royalty is associated with a Merck drug that currently is in late-stage human studies for treating osteoporosis. Celera has stated that the royalty equals a mid- to mid-high single digit percentage of revenues.

According to BVF, "if successful, the royalty asset could generate tremendous free cash flow for [Celera's] shareholders and, accordingly, this single asset could be worth a significant multiple of [Celera's] current market value."

It said in the filing that decoupling the asset from the "risks, vulnerabilities, and opportunities" of Celera's diagnostics business could help shareholder value. "Additionally, once the Merck royalty is carved out, [Celera] would be free to pursue strategic transactions without limiting the extraordinary potential upside of the royalty," BVF said.

Celera declined to comment on BVF's suggestion.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.